Medtronic hopes the $200 million purchase of telehealth firm Cardiocom will enhance its ability to respond to increasing demands on hospitals to better manage patient outcomes and costs. It will also greatly expand its customer base.

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.